Brunilda Shtylla
Nessuna posizione attualmente
Patrimonio netto: - $ in data 31/05/2024
Provenienza dei contatti di primo grado di Brunilda Shtylla
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 17 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Brunilda Shtylla tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
AMGEN INC. | Pharmaceuticals: Major | General Counsel | |
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Sales & Marketing | |
NEKTAR THERAPEUTICS | Pharmaceuticals: Major | Corporate Officer/Principal | |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
PALATIN TECHNOLOGIES, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
CURIS, INC. | Biotechnology | Director/Board Member | |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
The Trustees of Columbia University in The City of New York | College/University | Undergraduate Degree | |
UCB | Pharmaceuticals: Major | Corporate Officer/Principal | |
BAVARIAN NORDIC A/S | Pharmaceuticals: Major | Director/Board Member | |
MACROGENICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Northwestern University
Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses | College/University | Undergraduate Degree | |
The University of Chicago | College/University | Corporate Officer/Principal | |
LaSalle University | College/University | Undergraduate Degree | |
New York University | College/University | Undergraduate Degree | |
The Pennsylvania State University | College/University | Undergraduate Degree | |
St. John's University | College/University | Undergraduate Degree | |
AstraZeneca Canada, Inc.
AstraZeneca Canada, Inc. Pharmaceuticals: MajorHealth Technology AstraZeneca Canada, Inc. develops and manufactures pharmaceutical drug preparations. Its therapeutic areas include cardiovascular and metabolic disease, oncology, and respiratory, inflammation and autoimmunity. The firm also active in the infection, neuroscience and gastrointestinal disease areas. The company was founded in 1999 and is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | President | |
INSEAD | College/University | Masters Business Admin | |
University of California, Berkeley | College/University | Undergraduate Degree | |
University of California, Irvine | College/University | Doctorate Degree | |
University of Colorado Health Sciences Center | College/University | Doctorate Degree | |
University of Michigan | College/University | Undergraduate Degree Doctorate Degree | |
Ruprecht-Karls-Universität Heidelberg | College/University | Doctorate Degree | |
University of Zurich | College/University | Doctorate Degree | |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Pharmaceuticals: Major | Corporate Officer/Principal | |
UbiVac, Inc.
UbiVac, Inc. Pharmaceuticals: MajorHealth Technology UbiVac LLC engages in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases. The company was founded by Bernard A. Fox and Hong-Ming Hu in 2005 and is headquartered in Portland, OR. | Pharmaceuticals: Major | Director/Board Member | |
Center for Cancer Research | General Government | Corporate Officer/Principal | |
Kineta, Inc. (Washington)
Kineta, Inc. (Washington) Pharmaceuticals: MajorHealth Technology Kineta, Inc. engages in the development of novel immuno-therapies. It develops a pipeline of therapies that address critical unmet patient needs in oncology, chronic pain and biodefense. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH BiotechnologyHealth Technology Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany. | Biotechnology | Corporate Officer/Principal | |
VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Director/Board Member | |
The University of Chicago Booth School of Business | College/University | Masters Business Admin | |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Biotechnology | Director/Board Member | |
Temple University School of Pharmacy | College/University | Graduate Degree | |
CHECKMATE PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | President | |
Solebury Strategic Communications LLC
Solebury Strategic Communications LLC Miscellaneous Commercial ServicesCommercial Services Solebury Trout LLC engages in communications services. The company is headquartered in the United States. | Miscellaneous Commercial Services | Investor Relations Contact | |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Biotechnology | Chief Tech/Sci/R&D Officer | |
CULLINAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Society For Immunotherapy of Cancer
Society For Immunotherapy of Cancer Miscellaneous Commercial ServicesCommercial Services The Society for Immunotherapy of Cancer (SITC) is an organization that advances the science, development, and application of immunotherapy to improve cancer patient outcomes. The non-profit company is based in Milwaukee, WI. SITC conducts policy and advocacy efforts on behalf of its members and the field. The Journal for Immunotherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC, featuring original research articles, literature reviews, position papers, and discussions on all aspects of tumor immunology and cancer immunotherapy. SITC also created a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations. | Miscellaneous Commercial Services | President | |
IO BIOTECH, INC. | Biotechnology | Director/Board Member | |
Cardinal Health Specialty Solutions | President | ||
Kalobios Pharmaceuticals, Inc. | Corporate Officer/Principal | ||
VIRACTA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
89BIO, INC. | Pharmaceuticals: Major | Public Communications Contact | |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer |
Statistiche
Distribuzione geografica
Stati Uniti | 38 |
Svizzera | 4 |
Danimarca | 3 |
Germania | 3 |
Belgio | 2 |
Settori
Health Technology | 27 |
Consumer Services | 17 |
Commercial Services | 3 |
Government | 2 |
Finance | 2 |
Posizioni
Corporate Officer/Principal | 34 |
Director/Board Member | 28 |
Independent Dir/Board Member | 20 |
Chief Tech/Sci/R&D Officer | 19 |
Undergraduate Degree | 14 |
Contatti più connessi
Insiders | |
---|---|
Shalini Sharp | 17 |
Anne Borgman | 13 |
Jon Wigginton | 13 |
Arturo Molina | 13 |
Trevor Hallam | 10 |
Mark Lupher | 9 |
Heidi Hunter | 9 |
Jane Chung | 7 |
Annie Chang | 5 |
Hans-Peter Gerber | 5 |
Kristin Bedard | 4 |
Craig Berman | 4 |
Diana Landa | 4 |
Werner Rubas | 3 |
Regina Cheng | 2 |
- Borsa valori
- Insiders
- Brunilda Shtylla
- Connessioni Società